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Abstract
Recent studies have suggested distinctive biological properties and signaling mechanisms between human and mouse
embryonic stem cells (hESCs and mESCs). Herein we report that Shp2, a protein tyrosine phosphatase with two SH2
domains, has a conserved role in orchestration of intracellular signaling cascades resulting in initiation of differentiation in
both hESCs and mESCs. Homozygous deletion of Shp2 in mESCs inhibited differentiation into all three germ layers, and
siRNA-mediated knockdown of Shp2 expression in hESCs led to a similar phenotype of impaired differentiation. A small
molecule inhibitor of Shp2 enzyme suppressed both hESC and mESC differentiation capacity. Shp2 modulates Erk, Stat3 and
Smad pathways in ES cells and, in particular, Shp2 regulates BMP4-Smad pathway bi-directionally in mESCs and hESCs.
These results reveal a common signaling mechanism shared by human and mouse ESCs via Shp2 modulation of overlapping
and divergent pathways.
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Introduction
The establishment of human embryonic stem cell (hESC) lines
has generated a great deal of excitement in the fields of stem cell
biology and regenerative medicine [1]. It has been hoped that
hESCs and somatic stem cells could be potential sources of cells to
regenerate or rejuvenate damaged tissues. However the intracel-
lular signaling mechanisms that regulate hESC pluripotency and
differentiation are poorly understood, partly due to difficulties in
manipulating this type of stem cells in vitro. In the past few years,
much attention has been paid to transcription factors, such as
Oct4, Sox2 and Nanog, which are essential for the establishment
of human and mouse ES cell identity. Notably, these factors are
found to co-occupy a substantial portion of their target genes [2,3].
It has also been noted that a large set of developmental genes must
be repressed in hESCs to maintain pluripotency, and their
activation leads to ES cell differentiation [4]. The cytoplasmic
signaling cascades controlling hESC activities are largely un-
known.
Since mouse ES cells (mESCs) have received extensive
attentions in the past two decades and relatively more information
is available, characterization of hESC properties has been
naturally conducted by referencing mESCs. Comparative analyses
between hESCs and mESCs by several groups have defined
common and distinct marker gene expression patterns, cellular
properties and signaling mechanisms [5–8]. A number of
cytokines, such as leukemia inhibitory factor (LIF), bone
morphogenic protein 4 (BMP4), basic fibroblast growth factor
(bFGF) and Wnt are known to play critical roles in regulation of
mESC and/or hESC pluripotency in culture [9–11]. Interestingly,
LIF, a most critical cytokine for culture of pluripotent mESCs, is
found unnecessary for maintenance of hESC self-renewal in vitro
[12]. BMP4 works in concert with LIF in promoting mESC self-
renewal [13], while hESCs need the BMP antagonist, Noggin, for
suppression of differentiation in vitro [11,14]. One striking
difference in intracellular signaling mechanism between hESCs
and mESCs is the value of the Stat3 pathway. Stat3, which has a
critical role in maintaining mESC self-renewal [15], has been
found dispensable for hESCs [16,12,17]. However, activation of
the Erk pathway leads to differentiation in both human and mouse
ES cells, as expression of dominant negative mutants or use of
pharmaceutical inhibitors of Mek suppressed hESC and mESC
differentiation [18].
Shp2 is a cytoplasmic phospho-tyrosine phosphatase with two
Src-homology 2 (SH2) domains at the NH2-terminus that
modulates signal strength downstream of cytokine/growth factor
receptors [19–21]. In particular, Shp2 has been shown to play a
critical role in regulation of hematopoietic stem cell commitment
and differentiation into all blood cell lineages, and somatic gain of
function mutations in PTPN11/Shp2 are implicated in leukemo-
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4914genesis in human patients [22–26]. In this study, we have
conducted a comparative analysis of Shp2 functions in mouse
and human ES cells, by using combined genetics and chemical
biology approaches. We established and characterized homozy-
gous Shp2 null mutant mESC lines, and we examined the effect of
Shp2 knockdown on hESC differentiation using the small RNA
interference technology. By screening a chemical library, we
isolated a selective Shp2 enzyme inhibitor that can suppress
differentiation potential of both mESCs and hESCs. Together, our
experimental results indicate that Shp2 has a conserved role in
promoting differentiation of both mouse and human ES cells, via





flox mice has been described previously [27].
TheShp2
+/floxfertilizedeggswereinjectedwithpCMV-Cre(pBS185)
plasmid DNA to generate Shp2
+/2 mice. The Shp2
+/2 mice were
further crossed with UBC-GFP mice to generate Shp2
+/2:GFP mice.
The resultant Shp2
+/2:GFP mice in C57BL/6 background were
backcrossed with 129/sv wt mice for two generations. To derive
mESC lines, Shp2
+/2: GFP mice were intercrossed, and
blastocysts (E3.5) were collected and cultured as described
previously [28]. Briefly, blastocysts were collected in M2
medium, and seeded on irradiated mouse embryonic fibroblasts
(MEFs) in standard mESC medium supplemented with LIF
(1,000 U/ml), for growth and expansion of mESCs. Genotyping
of established mESC lines was determined by PCR using
primers for wt allele: forward: 59-ACG TCA TGA TCC GCT
GTC AG-39, reverse: 59-ATG GGA GGG ACA GTG CAG
TG-39; Shp2
2 allele: forward: 59-CAG TTG CAA CTT TCT
TAC CTC-39, reverse: 59-GCA GGA GAC TGC AGC TCA
GTG ATG-39, as described previously [27].
ES cell culture
mESCs were maintained on irradiated primary MEFs in
standard mESC culture medium. Feeder-free cultures were
maintained on gelatinized tissue culture dishes. hESCs (H14,
H9, H1) were cultured on irradiated MEFs or Hs27 cells in
standard hESC medium 2 DMEM/F12 (Invitrogen) supplement-
ed with 20% (vol/vol) Knockout
TM Serum Replacement (Invitro-
gen), 0.1 mM 2-mercaptoethanol (Invitrogen), and 0.1 mM
nonessential amino acids (Invitrogen) in the presence of bFGF
(8 ng/ml, Invitrogen) or on Matrigel-coated dishes in MEF-
conditioned medium, CM (R & D Systems). To quantitate
proliferation, viable single mESCs were plated at 5000 cells per
well in gelatin-coated 96-well plates in triplicate. Cell proliferation
rates were determined by CytoQuant fluorescence assay [29,30],
and the relative proliferating rates were normalized against the cell
number at 12 hrs.
In vitro differentiation of mESCs
To assess self-renewal and differentiation, primary embryoid
bodies (EBs) were formed by seeding single-cell suspension of
mESCs at 10,000 cells/ml in standard mESC medium without
LIF. Secondary EBs were formed by dissociating primary EBs into
single cells and seeding 100,000 cells/ml in methylcellulose
medium 2 IMDM supplemented with 15% ES-Cult
TMFBS, 1%
methylcellulose (StemCell Technologies Inc), 2 mM L-Glutamine,
150 mM MTG, 25 mg/ml holo-transferin, 5 mg/ml ascorbic acid.
Colony forming assay was performed by re-seeding cells
dissociated from 1
st EBs onto feeder cells in the standard mESC
medium (+LIF).
Alkaline phosphatase (AP) staining and immunostainig
AP staining was performed using an alkaline phosphatase
detection kit (Millipore). For immunocytochemistry, cells were
fixed with 4% PFA for 30 min at room temperature. After
washing with PBS, cells were treated with PBS containing 5%
normal goat serum (Sigma), and 0.1% Triton X-100 for 60 min at
room temperature. Then, the cells were incubated in primary
antibody overnight at 4uC. Primary antibodies used include Oct3/
4, Sox2, Nanog, Ssea-1, SSEA-4, BRACHYURY, GATA4, TUJ1
(Abcam). Secondary antibodies used were Alexa488-conjugated
and Alexa594-conjugated IgG (Invitrogen). Nucleus was stained
with DAPI. Flow cytometry was performed using BD FACSCanto
analyzer with Alexa647-conjugated antibodies against Ssea-1
(Santa Cruz), Oct3/4, Sox2 (from BD pharmagen).
Transfection and in vitro differentiation of hESCs
H14 cells were cultured 3–4 days before transfection. Short
interfering RNAs specific for PTPN11/Shp2 (and the control RNAs
with scrambled sequence) were purchased from DHARMACON,as
4 oligonucleotide mixture. Sequences of the oligonucleotides are: 59-
GAACAUCACGGGCAAUUAAUU-39;5 9-GAACACUGGUGA-
UUACUAUUU-39;5 9-GAAACCAAGUGCAACAAUUUU-39;
59-GAAGCACAGUACCGAUUUAUU-39. The nucleotide mix-
ture (200 pmol) were mixed with ,2610
6 H14 cells in small clumps
in nucleofection solution (AMAXA, mouse ES nucleofection Kit),
nucleofection was performed with program A23, and cells were
slightly recovered in RPMI medium for 15 min at 37uC and then
seeded on Matrigel-coated dishes in CM (R & D Systems).
Unconditioned medium (UM, standard hESC medium without
bFGF) was used to induce differentiation at day 2.
Microarray analysis
Total RNA was extracted from feeder-free ES cells or EBs using
RNA extraction kit (Ambion) and was reverse-transcribed.
Microarray analysis was performed at the Burnham core facility
by using Illumina chips.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from feeder-free ES cells using RNA
extraction kit (Ambion) and was reverse-transcribed using
Superscript II (Invitrogen) to generate the first-strand cDNA.
Quantitative-PCR (Q-PCR) was performed with Power SYBR Q-
PCR reagent (Applied Bioscience). The primers for Q-PCR are
designed through Roche probe library and their sequence
information is provided in Table S1.
Molecular signaling analysis
For cytokine or growth factor stimulation, MEF cells or feeder-
free mESCs/hESCs were starved in DMEM with 0.5% FBS (for
MEFs and mESCs) or 0.5% SR (for hESCs) overnight (for MEFs)
or for 4–6 hrs (for ES cells) prior to stimulation with LIF
(1,000 U/ml, Millipore), bFGF (50 ng/ml, Invitrogen), BMP4
(25 ng/ml, R & D Systems), IGF-1 (100 ng/ml, PEPROTECH),
PDGFbb (50 ng/ml, PEPROTECH). Immunoblotting analysis
was performed using antibodies specific for Shp2 (c-18, Santa
Cruz), Erk1/2, Stat3, Smad1 (Cell Signaling), Tubulin (Sigma),
and antibodies specific for p-Erk1/2 (Thr202/Tyr204), pY-
Stat3(Tyr705), p-Smad1 (Ser463/465)/Smad5 (Ser463/465)/
Smad8 (Ser426/428) (Cell Signalling).
Isolation and characterization of Shp2 inhibitors
A GST-tagged PTP domain of mouse Shp2 and Shp1 was
purified from E. Coli. Various PTPs (HePTP, LypCAT) and a
Shp2 in ESC Differentiation
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previously [31]. CD45 and PTP1B were purchased from
BIOMOL. GST-PTP domain of Shp2 protein (50 nmol) was
incubated with 1,280 compounds (10 mM each) from Lopac
TM
Library and 2,000 compounds (10 mM each) from Spectrum
TM
Library (Microsource Corporation) at room temperature for
10 min followed by addition of 1.5 mM pNPP to initiate the
reaction. After 30 min, the reaction was terminated with 1 M
NaOH, and PTPase activity was determined by measuring the
absorbance at 405 nm.
Molecular docking model of Shp2 inhibitor (DCA)
We performed molecular docking calculations for DCA using
the x-ray structure of Shp2 (PDB code: 2SHP) [32]. All docking
calculations were performed using FlexX module in SYBYL suite
from Tripos, Inc. The x-ray structure of Shp2 reveals that the
active site is a hydrophilic binding pocket and comprises of polar
residues such as D61, Y62, C459, and R465. DCA enters the
binding pocket (Figure S3c) and form interactions with residues
that comprise the wall of the binding pocket. The 2-hydroxyl
group forms a hydrogen bond with main chain amide of H426,
and the carbonyl group is involved in hydrogen bonding with side
chains of E361 and K366. The binding mode is further stabilized
by hydrogen bonding between 8-hydroxyl group of DCA, and
Q57 and D64. To look more closely, the carbonyl group in DCA
is placed close to two small binding pockets lined by residues E361
and K366 (Figure S3d, left panel A). 2-hydroxy moiety is placed
near a groove (Figure S3d, left panel B). This groove is lined by
residues such as N37, T59, and H426. These positions could be
modified to achieve optimal interactions with the binding pockets.
Results
Isolation and characterization of Shp2 null mutant mESC
lines
In previous work, we generated homozygous mutant mES cell
lines for a targeted deletion of exon 3 at the Ptpn11/Shp2 locus
[22,33]. This in-frame deletion results in production of a truncated
mutant protein Shp2
D46–110, lacking amino acids 46–110 in the
SH2-N domain. The homozygous mutant mESC lines for exon 3
deletion were isolated upon selection of heterozygous mutant cells
with high dosages of G418, which may induce chromosome loss in
ES cells. These two issues have possibly confounded the
interpretation of experimental results from analysis of exon3
2/2
cells. To unequivocally define the role of Shp2 in regulation of
mESC activities, we sought to establish Shp2 null mutants. In
recent experiments, we created a conditional Shp2 knockout
(Shp2
flox) allele in mice by inserting two loxP sites into introns that
flank exon 4 of Shp2. Deletion of exon 4 results in generation of a
null mutant allele of Shp2 [27]. Following pronuclear injection of
a Cre expression plasmid (pBS185) into Shp2
flox/+ fertilized eggs,
we generated Shp2
+/2 mice. The Shp2
+/2 mice were further
crossed with C57BL/6-Tg(UBC-GFP) 30Scha/J mice and the
heterozygotes were backcrossed with 129/sv mice. We did not find
any surviving Shp2
2/2 embryos at E6.5 (data not shown),
consistent with results of Yang et al [34], while homozygous
Shp2 mutant embryos with exon 3 deletion die later in the uterous,
around E7.5–10.5 [35]. However, we were able to isolate pre-
implantation embryos at the blastocyst stage (E3.5) from pregnant
Shp2
+/2: UBC-GFP females bred with Shp2
+/2 males, and
established GFP
+ mES cell lines from the inner cell mass as
described previously [28]. Despite the early embryonic lethality
due to Shp2 deletion, mESCs were successfully derived from
Shp2-deficient (Exon4
2/2) (nearly 25%), wild-type (Shp2
+/+) and
heterozygous (Shp2
+/2) blastocysts, as detected by PCR genotyp-
ing (Figure 1A, upper panel), and ablation of Shp2 was confirmed
by immunoblotting (Figure 1A, lower panel). Shp2
2/2 mESCs
displayed decreased proliferation and similar survival rates as
compared to wt mESCs (Figure S1A, S1B).
Shp2
2/2 mESCs exhibit reduced differentiation capacity
with improved self-renewal potential
When cultured in standard mESC medium, all of the Shp2
2/2
mESC clones contained densely packed cells, with smooth outline
and no differentiated cells at the edges. The Shp2
2/2 mESC
colonies were positive for alkaline phosphatase (AP) staining after
20 passages (Figure 1B). However, the wt mES cells, like other
mESC lines available, showed approximately 5–10% spontaneous
differentiation under the same culture condition. Shp2-deficient
mESCs expressed high levels of Ssea-1 as determined by FACS
analysis (Figure 1C). Embryoid body (EB) formation assay was
performed to evaluate mESC differentiation potential. After 8-day
incubation in differentiation medium, the expression of Nanog,
Oct4, and Sox2 remained high in Shp2-deficient EB cells, in
contrast to their dramatically decreased expression levels detected
only in the core area of wt EBs (Figure 2A). Flow cytometry
demonstrated sustained expression of Ssea-1 on Shp2
2/2 EB cells
at levels comparable to that of undifferentiated ES cells, while wt
EB cells had dramatically declined Ssea-1 expression (Figure 2A).
Furthermore, dissociated primary Shp2
2/2 EB cells can form
ESC-like AP
+ colonies much more efficiently than isolated wt EB
cells, when seeded on feeder cell layer and cultured in standard
mESC culture medium (Figure 2B). The secondary EB formation
efficiency of isolated primary Shp2
2/2 EB cells was 10 fold higher
than wt EB cells (Figure 2C). Together, these data suggest that
ablation of Shp2 resulted in inhibition of mESC differentiation
and improved maintenance of pluripotency.
Shp2 deletion suppresses mESC differentiation into all
three germ layer cell lineages
Microarray analysis data collected at different time points
(Figure S2A) show dramatically impaired differentiation capacity
of Shp22/2 mESCs. The overall gene expression profiles were
very similar in Shp2-deficient mESCs examined at 0, 2 and 8 days
of differentiation, in contrast to wt ES cells that exhibited
dramatically different expression patterns during this time period.
Sustained expression of pluripotent ESC marker genes (Nanog,
Oct3/4, Rex1 and Sox2) in Shp2 mutant cells were confirmed by
RT-PCR (Figure S2B), immunoblotting (Figure S2C), and
quantitative real time RT-PCR (qRT-PCR) analysis (Figure 2D).
In contrast, significantly lower expression was detected in Shp2
2/2
than in wt EB cells at day 10, for genes that are predominantly
expressed in various differentiated cell lineages, such as Nestin (in
ectoderm), Brachyury (T) and Desmin (in mesoderm), and Gata4,
Myf5 and Mef2C (in endoderm) (Figure 2D). In addition,
microarray analysis also detected significantly lower expression
of Sox17, Sox 7 and Foxa2 in Shp2
2/2 than in wt EB cells at day 8
(Figure S2A). Therefore, Shp2 is required for intracellular
signaling controlling exit of pluripotent mESCs for differentiation
into all three germ layers.
Shp2 knockdown leads to impaired hESC differentiation
We then asked whether Shp2 plays a similar role in control of
hESC differentiation, and used small RNA interference to
knockdown expression of PTPN11/Shp2 in hESCs. Transfection
of specific siRNA resulted in downregulation of Shp2 expression
by 80% in hESCs, lasting for one week (Figure 3A). Shp2
Shp2 in ESC Differentiation
PLoS ONE | www.plosone.org 3 March 2009 | Volume 4 | Issue 3 | e4914Figure 1. Establishment of Shp2
2/2 mESC lines. (A) Genotyping of genomic DNA (upper panel). The wild-type (wt) and exon 4
D alleles were
detected by PCR. Immunoblotting analysis for Shp2 confirmed the PCR results (lower panel), indicating that clones # 3, 7 and 11 are homozygous
(Shp2
2/2) mutants. (B) Alkaline phosphatase (AP) staining of wt and Shp2
2/2 mESCs cultured on feeder cells. Scale bars, 50 mm. (C) FACS analysis of
Ssea-1 expression on mESCs in feeder-free culture.
doi:10.1371/journal.pone.0004914.g001
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4 and SOX2 in H14 hES cells detected by immunostaining
(Figure 3B), and similar results were obtained for H1 and H9
hES cells (data not shown). Consistently, qRT-PCR analysis
demonstrated that Shp2 knockdown hESCs expressed higher
levels of NANOG, OCT3/4 and SOX2 than control cells, when
cultured in conditioned medium, CM (for maintenance) or un-
conditioned medium, UM (favoring differentiation) (Figure 3C).
Figure 2. Shp2
2/2 mES cells exhibit reduced differentiation capacity with improved self-renewal potential. (A) Immunostaining for
Nanog, Oct3/4, Sox2, and flow cytometry for Ssea-1 in primary (1
st) EBs cultured in LIF-free suspension medium for 8 days. Scale bars, 10 mm. (B)1
st
EBs were dissociated into single cells and re-seeded at the density of 1610
6 cells/ml onto feeder cells and cultured in ES cell standard medium (+LIF)
for colony forming assay. The cells were fixed and AP-stained. The AP-positive cells were counted under a bright field microscope. Scale bars, 200 mm.
(C)1
st EBs were dissociated into single cells and re-seeded at the density of 1610
6 cells/ml in the same medium as 1
st EBs for formation of secondary
(2
nd) EBs. Scale bars, 200 mm. The number of 2
nd EBs was counted under a bright field microscope. (D) Total RNA was extracted from mESCs (day 0)
and differentiating EBs at day10, and qRT-PCR was performed, and the relative values were normalized by CPH. Relative value changes of Shp2
2/2
over wt mESCs were indicated (n.3, * P,0.05, ** P,0.01).
doi:10.1371/journal.pone.0004914.g002
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PLoS ONE | www.plosone.org 5 March 2009 | Volume 4 | Issue 3 | e4914Figure 3. Shp2 knockdown in hESCs leads to impaired differentiation. (A) Immunoblotting and qRT-PCR indicate efficient Shp2 knockdown
by 80% in hESCs. H14 cells were transfected with Shp2-specific (+siShp2) or non-specific siRNA (2siShp2), and cells were cultured on matrigel-coated
dishes in CM for 2 days, total cell lysates were immunoblotted with the indicated antibodies or total RNAs were extracted for qRT-PCR (n=3, **
P,0.01). (B) Immunostaining of NANOG, OCT3/4, SOX2 in hESCs. After transfection, H14 cells were cultured in CM for 2 days, then the medium were
changed to UM to induce differentiation for additional 6 days. Scale bars, 10 mm. (C) Total RNAs were extracted from hESCs cultured in CM or UM,
qRT-PCR was performed, and the relative values of Shp2 knockdown over control hESCs were indicated (n=3, * P,0.05, ** P,0.01).
doi:10.1371/journal.pone.0004914.g003
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levels of NESTIN and PAX6 for ectoderm, T and DESMINE for
mesoderm and GATA4 and SOX17 for endoderm. Under CM
culture condition, similar low basal expression levels of these
differentiated cell markers were detected between control and
Shp2 knockdown hESCs (Figure 3C). However, after 6-day
incubation in UM, control hESCs differentiated rapidly with
marked increase in expression of genes that are preferentially
detected in three germ layer cell lineages, while Shp2 knockdown
resulted in significantly impaired expression of these differentiated
cell marker genes (Figure 3C). Thus, the Shp2 function in
promoting initial differentiation is conserved between mouse and
human ES cells.
Shp2 modulates common and distinct pathways in mES
and hES cells
As the Erk, Stat3 and Smad pathways have been implicated in
regulation of ESC self-renewal and differentiation [15,13,11,18],
we investigated how Shp2 modulates these signaling events in
mES and hES cells. LIF, BMP4 and bFGF potently induced
Erk1/2 activation in wt mESCs, while p-Erk signals were
decreased or blunted in Shp2
2/2 mESCs (Figure 4A). In contrast,
basal and LIF-stimulated pY-Stat3 signals were enhanced in
Shp2
2/2 mESCs, compared to that in wt cells (Figure 4A). These
results suggest a bi-directional regulation by Shp2 of Erk and Stat3
pathways in promoting mESC differentiation, similar to the
observation made in neural stem cells [30]. Consistently, p-Erk
signals were decreased in Shp2 knockdown hESCs following
treatment with bFGF, but not BMP4 (Figure 4B). Therefore, Shp2
has a conserved role in promoting signaling through Erk in both
mESCs and hESCs. However bFGF, BMP4 or LIF did not elicit a
robust induction of pY-Stat3 signal in hESCs (Figure 4A and data
not shown), reinforcing the notion that the LIF-Stat3 pathway,
although critical for mESC self-renewal [36,15], is dispensable in
hESCs [16,12,17].
Shp2 modulates the BMP-Smad pathway bi-directionally
in mouse and human ES cells
Interestingly, Shp2 ablation in mESCs resulted in increased p-
Smad1/5/8 signals following BMP4 treatment, but not LIF
stimulation (Figure 4A). In contrast, decreased levels of p-Smad1/
5/8 were detected in Shp2 knockdown hESCs following BMP4
(but not bFGF) stimulation, compared to that in control cells
(Figure 4B). These results suggest opposite effects of Shp2 on
BMP4-Smad signaling in mESCs and hESCs. To corroborate and
extend these observations, we performed qRT-PCR analysis of
expression profiles for genes downstream of the BMP4-Smad
pathway. Results in Figure 4C and 4D demonstrate significantly
increased BMP4 induction of Id1 and Id3 expression in Shp2
2/2
mESCs compared to wt cells, while BMP4-stimulated ID2 and ID3
expression levels were lower in Shp2 knockdown than in control
hESCs. Notably, BMP4-Smad signaling has been shown to work
cooperatively with LIF-Stat3 pathway in supporting mESC self-
renewal [13]. However, BMP4 can induce trophoblast differen-
tiation in hESCs and a BMP antagonist, Noggin, acts to support
hESC self-renewal in coordination with bFGF [11]. Thus, Shp2
may act to orchestrate hESC/mESC differentiation at least in part
through bi-directional regulation of BMP4-Smad signaling in the
two types of stem cells. Modulation of BMP4-Smad signal strength
by Shp2 may involve direct and indirect mechanisms, cross-talks
between Erk, Stat3 and Smad pathways have been documented in
the literature [37].
Shp2 inhibitors attenuate both mESC and hESC
differentiation
The conserved function of Shp2 in mESC/hESC differentiation
prompted us to search for Shp2 inhibitors. By screening the
Lopac
TM and Spectrum
TM library (Microsource Corporation), we
identified 56 compounds that showed potent inhibitory effect on
Shp2 catalytic activity, and three of these compounds exhibited
highly selective inhibition on Shp2 (Figure S3A). In this study, we
focused on 7-deshydroxypyrogallin-4-carboxylic acid (DCA)
(Figure S3B), with an IC50 on Shp2 as 2.1 mM, but much less
active on several other tyrosine phosphatases tested, including
HePTP, LypCAT, CD45, PTP1B and a dual specificity
phosphatase VHR (Figure S3C). A similar inhibitory effect on
Shp1 (IC50: 2.3 mM), a close relative of Shp2, does not affect our
experimental results, since Shp1 is not expressed in ES cells. Ki
determination suggests that DCA may function as a mixed type
(competitive and/or uncompetitive) inhibitor with low value
(2.6 mM). A computer-based docking model shows that DCA
can access and enter the pocket located in the PTP domain (Figure
S4A, S4B). DCA suppressed growth factor-stimulated Erk activity
in cells, as evaluated by both kinase assay using MBP as substrate
and immunoblotting against p-Erk1/2 (Figure S3D), consistent
with a positive role of Shp2 in mediating Erk activation by growth
factors [19,20]. Of Note, DCA did not affect IGF-1 stimulated Erk
activation in Shp2
2/2 mESCs (Figure S5A), indicating specificity
of the compound toward Shp2. Furthermore, DCA treatment had
no effect on IGF-1-stimulated Akt activity in wt and Shp2
2/2
mESCs, ruling out the possibility of non-specific DCA interference
in cell signaling (Figure S5A). DCA at high concentration
(100 mM) showed inhibitory effect on ESC proliferation, with no
toxicity to both mouse and human ES cells at low concentrations
(Figure S5B). Furthermore, mES cell proliferation rate can be
restored following removal of the compound from culture
medium, suggesting its reversible effect (Figure S5C).
We analyzed DCA effect on mESC and hESC differentiation.
Supplement of DCA in un-conditioned medium partially sup-
pressed mESC and hESC differentiation, as monitored by Oct3/4,
Nanog and Sox2 expression (Figure 5A, 5B). DCA at low dosages
was not sufficient to maintain ESC pluripotency when added into
the culture medium, while high dosages of DCA were toxic to ES
cells. Chemical modification of DCA may improve its efficacy and
specificity and we will also expand our screening of chemical
libraries to search for more efficient Shp2 inhibitors. In this study,
we sought to compose a cocktail consisting of DCA and two other
compounds, PD98059 (Mek inhibitor) and BIO (Gsk3 inhibitor),
which were shown to partially inhibit mESC/hESC differentiation
[38,18]. Combination of these three compounds at low concen-
trations efficiently suppressed mESC differentiation in LIF- and
feeder-free culture medium without significant impact on cell
proliferation rate (Figure 5C, 5D). mESCs maintained with the
cocktail inhibitors expressed high levels of AP and Ssea-1 for up to
20 passages (Figure 5C). We also observed a similar effect of the
cocktail inhibitors in suppressing hESC differentiation. qRT-PCR
analysis demonstrated increased expression levels of pluripotent
stem cell markers, OCT3/4 and REX-1, accompanied by
decreased expression of differentiated cell markers NESTIN, T
and GATA4 (Figure 5E). hESCs were passaged in feeder-free
medium supplemented with cocktail inhibitors for at least three
generations without obvious differentiation (Figure 5F) and
restored differentiation into three cell lineages following drug
removal (Figure 5G), suggesting reversible effect of the inhibitors.
Therefore, this chemical biology approach renders support to the
genetic data that suggest a conserved role of Shp2 in control of
mESC and hESC differentiation.
Shp2 in ESC Differentiation
PLoS ONE | www.plosone.org 7 March 2009 | Volume 4 | Issue 3 | e4914Discussion
The intracellular signaling mechanism for the switch between
self-renewal and differentiation of ES cells is a central and
unanswered question in stem cell biology, and the initiation of
ESC differentiation is apparently determined by multiple path-
ways working in concert. This complexity requires a modulator(s)
that fine-tunes signals coordinately in negative or positive fashion,
although little is known in this regard. We demonstrate here that
Shp2 acts as a negative or positive regulator of signaling
events controlling self-renewal and differentiation of mESCs and
hESCs.
In this study, we have taken three different experimental
approaches to determine Shp2 functions in human and mouse ES
cell differentiation. First, we established homozygous mutant mES
cell lines with a targeted deletion of exon 4 at the Shp2 locus. Shp2-
deficient mES cells displayed dramatically impaired capacity of
differentiation into all three germ layer cell lineages, accompanied
by improved self-renewal potential. These results clearly define a
biological function of Shp2 in control of mouse ES cell
Figure 4. Shp2 modulates various signaling pathways in mES and hES cells. (A) LIF/BMP4 signaling in mESCs. mESCs were stimulated by LIF
(1,000 units/ml) or BMP4 (25 ng/ml) for 15 mins after overnight starvation. Total cell lysates were immunoblotted with the indicated antibodies. (B)
bFGF/BMP4 signaling in hESCs (H14). The indicated antibodies were used to analyze proteins in hESCs stimulated by bFGF (50 ng/ml, 15 mins) or
BMP4 (25 ng/ml, 30 min) after 6-hour starvation. (C, D) mESCs (left) or hESCs (right) were treated with BMP4 for 60 mins and total RNAs were
analyzed for Id expression levels (Mean6SEM, n=3). (a, c, e) mESCs; (b, d, f) hESCs.
doi:10.1371/journal.pone.0004914.g004
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PLoS ONE | www.plosone.org 8 March 2009 | Volume 4 | Issue 3 | e4914Figure 5. Chemical Inhibitors suppress mESC and hESC differentiation. (A) DCA partially inhibits differentiation in both mESCs (left panel)
and hESCs (right panel) monitored by qRT-PCR analysis of Oct3/4 expression. (B) qRT-PCR analysis of pluripotent cell markers Nanog and Sox2. mESCs
were incubated in feeder-free and LIF-free medium in the absence or presence of 50 mM DCA for 6 days and total RNAs were extracted for analysis
(Mean6SEM, n=3). (C) AP staining (left panel) and Ssea-1 flow cytometry (right panel) of mESCs treated with or without cocktail inhibitors. Scale
bars, 50 mm. (D) mESCs cultured in feeder-free and LIF-free medium with cocktail inhibitors exhibited comparable proliferation rate as cells cultured
in standard mESC medium (+LIF). (E) QRT-PCR analysis of pluripotent cell markers OCT3/4 and REX-1, or differentiated cell markers NESTIN, T and
GATA4. hESCs were incubated in CM, or UM in the absence or presence of cocktail inhibitors as indicated (25 mM DCA, 25 mM PD and 0.5 mM Bio) for 6
days (Mean6SEM, n=3). (F) Morphological analysis of hESCs performed by immunostaining of OCT3/4, and SSEA-4. Scale bar, 10 mm. (G) Removal of
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from Shp2 mutant (exon 3
2/2) mES cells in our previous
experiments [33,25], supporting the notion that targeted deletion
of exon 3 at the Ptpn11/Shp2 locus created a loss of function
mutant Shp2 molecule. Second, to extend the functional analysis
of Shp2 from mouse to human ES cells, we have successfully used
the siRNA approach to knockdown Shp2 expression in hESCs,
unveiling a similar role of Shp2 in promoting human ES cell
differentiation. Thus, the Shp2 function in promoting ES cell
differentiation is conserved between mESCs and hESCs, despite a
body of literature documenting differences existing between the
two types of ES cells [5–8]. Third, a small molecule inhibitor of
Shp2 enzyme has been identified that partially inhibits mouse and
human ES cell differentiation at low dosages. This chemical
biology experiment not only renders strong support to our gene
knockout and knockdown experiments, but also suggests that
development of specific Shp2 inhibitors can provide useful
experimental tools for amplification of hESCs in vitro for
molecular analysis and biological characterization.
Our results suggest different molecular mechanisms underlying
the concerved function of Shp2 in regulation of mouse and human
ES cell differentiation. In mouse ESCs, Shp2 participates in
modulation of LIF signals by promoting the Erk pathway and
suppressing the Stat3 signal. Upon LIF stimulation, Shp2 is
physically recruited to gp130, the signaling component of LIF
receptor, and acts to regulate the LIF signal [39,25]. Bi-directional
regulation of Erk and Stat3 pathways by Shp2 appears to be
conserved in embryonic and adult stem cells as well as in
differentiated cell types. In previous work, we have found opposite
effects of Shp2 deletion on Erk and Stat3 activation in coordinated
regulation of neural stem cell proliferation and differentiation into
neuronal/glial cell lineages during brain development [30], and
also in control of energy balance by leptin in hypothalamic
neurons of adult brain [27]. In addition, we detected a similar
fashion for Shp2 regulation of Erk and Stat3 activation in
hepatocytes during liver regeneration and epithelial cells in
mammary gland development and involution [40,41]. Both the
decreased Erk activity and enhanced Stat3 signals may lead to
suppression of mES cell differentiation and improved self-renewal.
Attenuation of Erk signal may also be responsible for the
decreased proliferation rate observed in Shp2
2/2 mESCs and
Shp2 knockdown hESCs as well as in mESCs/hESCs treated with
Shp2 inhibitors. Activation of the Stat3 pathway may lead to
different physiological consequences in various cell types. The LIF-
Stat3 signaling appears to be required for self-renewal in mESCs
[36,15], while activation of Stat3 promotes glial cell differentiation
from neural stem/progenitor cells during cell fate specification in
the brain [42]. On the other hand, Stat3 is required for timely
initiation of physiological epithelial cell apoptosis during mamma-
ry gland involution [43]. Consistent with the literature [16,12,17],
we did not detect Stat3 activation signals in hESCs under a variety
of growth factor/cytokine stimulation, supporting the theory that
the Stat3 pathway is not required for hESC self-renewal.
One interesting observation made in this study is the bi-
directional regulation of BMP4-Smad signaling by Shp2 in mouse
and human ES cells. Genetic ablation of Shp2 in mouse ES cells
resulted in enhanced p-Smad1/5/8 signals in response to BMP4
stimulation and, consistently, increased expression of Id1 and Id3,
target genes downstream of the BMP4-Smad pathway, was
detected in Shp2
2/2 mESCs compared to wild-type cells. In
contrast, Shp2 knockdown in hESCs leads to impaired p-Smad1/
5/8 levels following BMP4 treatment. Consistent to this
observation is the decreased induction of ID2 and ID3 gene
expression by BMP4 in Shp2 knockdown hESCs. These results
suggest a cell context-dependent manner for Shp2 regulation of
the BMP4-Smad pathway in hESCs and mESCs. Interestingly,
this bi-directional modulation of Smad signaling can lead to the
same consequence of differentiation suppression in human and
mouse ES cells. BMP4-Smad signaling has been shown to work
cooperatively with the LIF-Stat3 pathway in supporting mouse ES
cell self-renewal [13]. However, BMP4 can induce trophoblast
differentiation in human ES cells , and Noggin, a BMP antagonist,
has been shown to support hESC self-renewal in concert with
bFGF [11]. It is unclear yet how Shp2 regulates the BMP4-Smad
pathway, which may involve direct and indirect mechanisms. For
example, Shp2 may influence Smad signaling strength via
regulation of Erk and Stat pathways, since cross-talks between
Erk, Stat and Smad pathways have been reported previously by
several groups [37].
Deletion of Shp2 also resulted in reduced mESC proliferation,
suggesting a role of Shp2 in mitogenic signaling. Consistently, we
observed reduced proliferation rate of hESCs when Shp2
expression is downregulated by siRNA, and supplement of Shp2
inhibitor DCA leads to reduced cell proliferation of both hESCs
and mESCs. However, the reduced differentiation capacity of
Shp2-deficient ES cells is unlikely due to decreased proliferation
rate. In contrast, the primary and secondary EB formation assay
detected dramatically increased self-renewing proliferation of
Shp2
2/2 mES cells, as compared to wt cells. Furthermore,
molecular signaling analysis strongly suggests that Shp2 ablation
suppressed pathways favoring differentiation, while enhancing
signals leading to self-renewal. The cross-talk and balance of
proliferation, self-renewal and differentiation signals modulated/
coordinated by Shp2 contribute to the switch between pluripo-
tency and differentiation of ES cells.
We have identified a potent and selective Shp2 inhibitor by
screening a small chemical library. The specificity of Shp2
inhibition by DCA has been tested and confirmed by a number
of experiments in this study: a) inhibition of purified Shp2 was
examined against a list of other PTPs; b) DCA was shown to
suppress growth factor-stimulated Erk activation; c) DCA was
found to have no effect on Shp2
2/2 cells. As expected, the
inhibitors can suppress growth factor-stimulated Erk activation
and also cell proliferation. Importantly, DCA exhibits similar
inhibitory effects on mouse and human ES cell differentiation. In
recent experiments, several groups have shown similar effects with
Mek inhibitor and GSK3 inhibitor on mouse or human ES cells
[38,18]. One concern with small molecule inhibitors is often
associated with their toxicity that limits their value in their use for
long-term hESC culture. We have used an inhibitor cocktail and
our results show that in combination, these molecules can be used
at much lower concentrations to reach a similar biological effect.
Further chemical modification of the isolated small molecule in
order to increase specificity and reduce toxicity will increase the
application value.
In summary, multiple pathways, including Erk, Stat3 and
Smad, have been shown to participate in cellular decisions for
ESC self-renewal or differentiation; this study identifies Shp2 as a
cocktail inhibitors restored differentiation capacity. hESC cells maintained with the cocktail inhibitors were incubated in UM without inhibitors for 8
days and allowed for differentiation under standard procedures. Cells were immunostained for TUJ1
+ neurons, GATA4
+ endoderm cell lineage or T
+
mesoderm cell lineage, and hES cells incubated in CM were immunostained for OCT3/4. Scale bar, 5 mm.
doi:10.1371/journal.pone.0004914.g005
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differentiation of human and mouse ES cells.
Supporting Information
Figure S1 Growth, survival and differentiation of Shp22/2
mES cells. (A) Proliferation rate. mESCs were seeded on gelatin-
coated plates at 50,000 cells/ml in the absence of feeder cells and
cell numbers were determined by CytoQuant fluorescence assay at
12, 24, 36, 48, 72 hrs after seeding. The cell numbers were
normalized against the value at 12 hrs (Mean6SEM, n=4). (B)
Immunostaining of BrdU+ cells (red) co-labeled with DAPI (blue)
after 4 hr incubation (upper panel). Annexin V staining for cell
apoptosis (lower panel). Scale bar, 20 mm.
Found at: doi:10.1371/journal.pone.0004914.s001 (1.73 MB TIF)
Figure S2 Gene expression profiles during mESC differentia-
tion. (A) Total RNAs were extracted from three seperate mESC
lines for both WT and Shp22/2 during differentiation at various
time points as indicated. The microarray data collected from the
triplacate samples were grouped and analysed by GeneSpring GX
Software (Agilent Technologies). (B) Total RNA samples collected
at different time points during differentiation were subjected to
RT-PCR for Oct3/4 detection. (C) The whole cell lysates collected
at different time points during differentiation were subjected to
immunoblotting by Oct3/4 and Nanog antibodies.
Found at: doi:10.1371/journal.pone.0004914.s002 (2.20 MB TIF)
Figure S3 Isolation of Shp2 inhibitors. (A) Screening procedure
of chemical library. (B) The chemical structure of DCA. (C) IC50
values of DCA against various PTPs. (D) DCA inhibits Erk
phosphorylation and activity in MEFs. Overnight-starved MEFs
were treated with increasing dosages of DCA: 5, 20, 100 mM for
1 hr followed by stimulation with PDGFbb (50 ng/ml, 5 min).
pErk1/2 was detected in whole cell lysates. Erk1/2 was
immunoprecipitated from cell lysates and kinase activity was
measured using myelin basic protein (MBP) as substrate (with
[32P]ATP). After autoradiography, the membrane was used for
immunoblotting analysis of Erk1/2. Total cell lysates were also
immunoblotted as indicated.
Found at: doi:10.1371/journal.pone.0004914.s003 (2.01 MB TIF)
Figure S4 Computerized model for DCA interaction with Shp2.
(A) A computerized mode of DCA binding to the active site of
Shp2. (B) A: zoomed in view of DCA in the active site of Shp2
shows the carboxylic acid group which is placed close to small
binding pockets (indicated by a white arrow). B: the 2-hydroxyl
group is situated near a groove, indicated by a white arrow.
Found at: doi:10.1371/journal.pone.0004914.s004 (2.01 MB TIF)
Figure S5 Biological activity of Shp2 inhibitor (DCA). (A)
Specificity of DCA in mESCs. Overnight-starved mESCs were
treated with 50 mM DCA for 1 hr followed by stimulation with
IGF-1 (100 ng/ml) for 10 min. Total cell lysates were immuno-
blotted with the indicated antibodies. (B) CytoQuant fluorescence
assay for proliferation of mESCs treated with DMSO or DCA
(20 mM or 100 mM). The data shown are means6SEM, n=4). (C)
Reversible effect of DCA on mESCs proliferation. After
pretreatment with 100 mM DCA for 36 hrs, mESCs were washed
with PBS 3 times and then cultured in the same medium but with
DMSO, up to 72 hrs (Means6SEM, n=4).
Found at: doi:10.1371/journal.pone.0004914.s005 (2.35 MB TIF)
Table S1 DNA sequences of primers used for qRT-PCR.
Found at: doi:10.1371/journal.pone.0004914.s006 (0.06 MB
DOC)
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